Thought bubble: JPM's AI buzz
At the recent JPMorgan Healthcare Conference, the conversation around biotech is buzzing with AI potential, although no fully AI-developed drugs are on the market yet. Expect FDA approval for the first AI-enabled drug in two to three years, with companies focusing on bolstering in-house AI capabilities. Additionally, the hype around AI is attracting more investment into biotech, signaling exciting times ahead.